Neural Prolotherapy for Trigeminal Neuralgia

  • Ankur Khandelwal
  • Girija Prasad Rath


Trigeminal neuralgia (TGN) is a syndrome of unilateral, lancinating, paroxysmal, stabbing orofacial neuropathic pain, confined to the distribution of one or more of the branches of the trigeminal nerve. Most of the patients respond well to pharmacotherapy; carbamazepine and oxcarbazepine being the first line treatment. Surgical options are available if medications are no longer effective or tolerated. Microvascular decompression, gamma knife radiosurgery, and percutaneous rhizotomies are most promising surgical alternatives [1, 2]. Recently, neural prolotherapy has been described in relation to the management of TGN. It is also known as perineural injection therapy (PIT) and is one of the latest advancements in regenerative medicine. First described by Dr. Paul Pybus and Dr. Roger Wyburn-Mason, PIT targets neurogenic inflammation in subcutaneous nerves that potentially generates pain [3, 4]. It was further refined by Dr. John Lyftgoft using hypertonic dextrose injection, which provided substantial pain control in a series of 300 Achilles tendinopathy [5]. He described the technique as subcutaneous injections of 0.5–1 mL of hypertonic dextrose and local anesthetic at each tender point alongside the affected tendon and thereafter repeating the treatment at weekly intervals. This was a departure from the traditionally described prolotherapy in which a more concentrated proliferant is injected directly into the enthesis of an affected structure causing discomfort and increased pain at the time of injection and in the immediate following few days.


  1. 1.
    Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015;20:107–14.CrossRefGoogle Scholar
  2. 2.
    Feller L, Khammissa RAG, Fourie J, Bouckaert M, Lemmer J. Postherpetic neuralgia and trigeminal neuralgia. Pain Res Treat. 2017;2017:1681765.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Reeves KD, Lyftogt J. Prolotherapy: regenerative injection therapy. In: Waldman SD, editor. Pain management. 2nd ed. Philadelphia, PA: Saunders (Elsevier); 2011. p. 1027–44.CrossRefGoogle Scholar
  4. 4.
    Geppetti P, Holzer P. Neurogenic inflammation. Boca Raton, FL: CRC Press; 1996.Google Scholar
  5. 5.
    Lyftogt J. Subcutaneous prolotherapy for achilles tendinopathy: the best solution? Aust Musculoskeletal Med. 2007;122:107–9.Google Scholar
  6. 6.
    Conaway E, Browning B. Neural prolotherapy for neuralgia. J Prolotherapy. 2014;6:928–31.Google Scholar
  7. 7.
    Itkin A. Treatment of trigeminal neuralgia utilizing neural prolotherapy: a case report. J Prolotherapy. 2016;8:961–5.Google Scholar
  8. 8.
    Thor JA, Mohamed Hanapi NH, Halil H, Suhaimi A. Perineural injection therapy in the management of complex regional pain syndrome: a sweet solution to pain. Pain Med. 2017;18:2041–5.CrossRefGoogle Scholar
  9. 9.
    Wu YT, Ho TY, Chou YC, et al. Six-month efficacy of perineural dextrose for carpal tunnel syndrome: a prospective, randomized, double-blind, controlled trial. Mayo Clin Proc. 2017;92:1179–89.CrossRefGoogle Scholar
  10. 10.
    Hauser RA, Steilen DR, Fisher P. Upper cervical instability of traumatic origin treated with dextrose prolotherapy: a case report. J Prolotherapy. 2015;7:932–5.Google Scholar
  11. 11.
    Hauser RA, Feister WA. Treatment of basal thumb osteoarthritis: a retrospective study of dextrose prolotherapy injections as an alternative treatment. J Prolotherapy. 2013;5:913–21.Google Scholar
  12. 12.
    Lyftogt J. Subcutaneous prolotherapy treatment of refractory knee, shoulder and lateral elbow pain. Aust Musculoskeletal Med. 2007;12:110–2.Google Scholar
  13. 13.
    Weglein AD. Neural prolotherapy. J Prolotherapy. 2011;3:639–43.Google Scholar
  14. 14.
    Wheaton MT, Jensen N. The ligament injury-osteoarthritis connection: the role of prolotherapy in ligament repair and the prevention of osteoarthritis. J Prolotherapy. 2011;3:790–812.Google Scholar
  15. 15.
    Harris GR. Effective treatment of chronic pain by the integration of neural therapy and prolotherapy. J Prolotherapy. 2010;2:377–86.Google Scholar
  16. 16.
    Hauser RA, Gruen KA. The use of prolotherapy in the treatment of chronic overuse shoulder and neck pain, neurogenic pain and hip degeneration in an incomplete C4-C5 spinal cord injury patient. J Prolotherapy. 2009;1:166–71.Google Scholar
  17. 17.
    DM DC, Cortazzo MH. Regenerative medicine in the field of pain medicine: prolotherapy, platelet-rich plasma, and stem cell therapy—theory and evidence. Tech Reg Anesth Pain Manag. 2011;15:74–80.CrossRefGoogle Scholar
  18. 18.
    Alawi K, Keeble J. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther. 2010;125:181–95.CrossRefGoogle Scholar
  19. 19.
    Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. BJU Int. 2008;101(Suppl 3):2–6.CrossRefGoogle Scholar
  20. 20.
    Meng J, Ovsepian SV, Wang J, et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29:4981–92.CrossRefGoogle Scholar
  21. 21.
    Urano H, Ara T, Fujinami Y, Hiraoka BY. Aberrant TRPV1 expression in heat hyperalgesia associated with trigeminal neuropathic pain. Int J Med Sci. 2012;9:690–7.CrossRefGoogle Scholar
  22. 22.
    Rabago D, Nourani B. Prolotherapy for osteoarthritis and tendinopathy: a descriptive review. Curr Rheumatol Rep. 2017;19:34.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ankur Khandelwal
    • 1
  • Girija Prasad Rath
    • 1
  1. 1.Department of Neuroanaesthesiology and Critical Care Neurosciences CentreAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations